FDA approves first gene therapy for sickle cell disease in U.S.
The FDA has approved Casgevy, the first gene therapy for sickle cell disease, offering hope to 100,000 Americans — but high costs and limited access raise urgent equity concerns.
The FDA has approved Casgevy, the first gene therapy for sickle cell disease, offering hope to 100,000 Americans — but high costs and limited access raise urgent equity concerns.
